IP77: Bladder Cancer: Basic Research & Pathophysiology II
Monday, May 18, 2026 7:00 AM to 9:00 AM · 2 hr. (America/New_York)
147A
Poster and Podium Sessions
Basic Science ResearchOncology: Bladder
Information
Of Interest To
Researchers
Monday, May 18
IP77-01: Prospective analytical study using real-time Artificial Intelligence (AI) to optimize the diagnostic of bladder tumor detection.
Monday, May 18, 2026 7:00 AM to 9:00 AM
147A
Fabien SAINT
IP77-02: Discovery of a Rare Mesenchymal-Like Urothelial Cell Population Resembling the Phenotype of Sarcomatoid Component of MB49 Bladder Cancer Model
Monday, May 18, 2026 7:00 AM to 9:00 AM
147A
IP77-03: The Impact of Gemcitabine Pretreatment on Docetaxel Penetration in the Bladder
Monday, May 18, 2026 7:00 AM to 9:00 AM
147A
IP77-04: Hydroxyl radical-generating water prevents bladder tumor development through the induction of ferroptosis
Monday, May 18, 2026 7:00 AM to 9:00 AM
147A
IP77-05: RPS4X and RPS4Y1 drive recurrence of non-muscle-invasive bladder cancer by suppressing tumor antigen presentation
Monday, May 18, 2026 7:00 AM to 9:00 AM
147A
Meng Ding
IP77-06: Do concomitant auto-immune disorders alter the tumor immune microenvironment and subsequent effectiveness of BCG in non-muscle invasive bladder cancer: a mixed methods study
Monday, May 18, 2026 7:00 AM to 9:00 AM
147A
IP77-07: Spatial Transcriptomics of en bloc Transurethral Resection of Bladder Tumor Specimens Defines an Invasive-Front Gene Expression Signature in Bladder Cancer
Monday, May 18, 2026 7:00 AM to 9:00 AM
147A
IP77-08: Somatic Gene Alterations Associated with Nodal Status and Survival in Urothelial Bladder Cancer
Monday, May 18, 2026 7:00 AM to 9:00 AM
147A
Jeanpierre Kanumuambidi · East Carolina university, Brody School of medicine
IP77-09: Immune Oncology Gene and Protein Expression Differences in Urothelial Carcinoma at Primary Site and Lymph Node Metastasis
Monday, May 18, 2026 7:00 AM to 9:00 AM
147A
IP77-10: CD46 as a Theranostic Target in Bladder Cancer: Expression Profiling and Pre-Clinical Validation of [89Zr]Zr-DFO-YS5 PET in Bladder Cancer
Monday, May 18, 2026 7:00 AM to 9:00 AM
147A
IP77-11: Dissecting the tumor microenvironment of advanced urothelial carcinoma pre and post enfortumab vedotin ± pembrolizumab
Monday, May 18, 2026 7:00 AM to 9:00 AM
147A
IP77-12: Using ex vivo culture to evaluate dynamic changes in the bladder and prostate tumor microenvironment following durvalumab treatment.
Monday, May 18, 2026 7:00 AM to 9:00 AM
147A
IP77-13: Molecular mechanism of resistance to enfortumab vedotin (EV) and Nectin-4-modified molecular classification for muscle-invasive bladder cancer (MIBC)
Monday, May 18, 2026 7:00 AM to 9:00 AM
147A
IP77-14: DPP4 Upregulation Drives MMAE Resistance in Bladder Cancer: Therapeutic Potential of Combined Targeting
Monday, May 18, 2026 7:00 AM to 9:00 AM
147A
IP77-15: Inhibiting a2,6-Sialylation Boosts Enfortumab Vedotin Response by Stabilizing Nectin-4 and Enhancing Macropinocytic Uptake in Bladder Cancer
Monday, May 18, 2026 7:00 AM to 9:00 AM
147A
IP77-16: Spatial Immunophenotypes Combined with Neutrophil-to-Lymphocyte Ratio (NLR) Predict Response to Immune Checkpoint Inhibitors (ICIs) and Gemcitabine-Cisplatin Neoadjuvant Chemotherapy in Muscle-Invasive Bladder Cancer
Monday, May 18, 2026 7:00 AM to 9:00 AM
147A
IP77-17: Nanoparticles-mediated mitochondrial iron depletion reversed innate and adoptive immune-resistance to boost bladder cancer immunotherapy
Monday, May 18, 2026 7:00 AM to 9:00 AM
147A
Cheng Li
IP77-18: Inactivation of Androgen Receptor (AR) or Estrogen Receptor-ß (ERß) Enhances the Efficacy of Immune Checkpoint Inhibition in Bladder Cancer
Monday, May 18, 2026 7:00 AM to 9:00 AM
147A
IP77-19: Fibrate lipid-lowering drugs enhance the mechanism of immunotherapy for bladder cancer by inhibiting the expression of CD276
Monday, May 18, 2026 7:00 AM to 9:00 AM
147A
Cheng Li
IP77-20: Targeting EphA2 reverses immunotherapy resistance in Basal/Squamous bladder cancer via CCL5-mediated T-cell recruitment
Monday, May 18, 2026 7:00 AM to 9:00 AM
147A
IP77-21: Functional Antioxidants and B7-H3 Targeting in Immunocellular Therapy for Bladder Cancer
Monday, May 18, 2026 7:00 AM to 9:00 AM
147A
Chien-Hui Lin
IP77-22: Senescent cancer-associated fibroblasts as aged microenvironment develop bladder cancer by CXCL12 secretion
Monday, May 18, 2026 7:00 AM to 9:00 AM
147A
IP77-24: CDK1/HIF-1a Promotes FGFR3-Dependent Bladder Tumor Progression via Glycolytic Signaling
Monday, May 18, 2026 7:00 AM to 9:00 AM
147A
Jie Ming
IP77-25: Glucose-Regulated Protein 94 (GRP94) in Bladder Cancer Progression: Is It a “Double-Edged Sword”?
Monday, May 18, 2026 7:00 AM to 9:00 AM
147A
IP77-26: Decoding the Tumor Ecosystem: RNA-seq Profiling Reveals Microbiome–TME Coupling in Bladder Cancer
Monday, May 18, 2026 7:00 AM to 9:00 AM
147A
IP77-27: PRECLINICAL EVALUATION OF FUSOGENIC VACCINIA VIRUS EXPRESSING IMMUNOSTIMULATORY GENES IN SUBCUTANEOUS AND ORTHOTOPIC MOUSE MODELS OF BLADDER CANCER
Monday, May 18, 2026 7:00 AM to 9:00 AM
147A
IP77-29: Comprehensive multi-layered omics analysis of the UBC landscape for precision medicine and its clinical implications: from deciphering distinct molecular heterogeneity to guiding treatment decision-making and developing tailored therapeutic strat
Monday, May 18, 2026 7:00 AM to 9:00 AM
147A
